SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sean Janzen who wrote (85)11/1/1996 10:15:00 PM
From: Josh C. Pleasure, M.D.   of 1501
 
I disagree that TB antigen would stabilize IZP "in the event of an unfavorable result in the Human Clinical Trials of Apanol." All 50 of IZP's drugs are based on their novel drug class and bad results with Apanol would mean IZP is in serious trouble. This is my opinion.

Based on animal data, I consider adverse side effects or poor clinical results of any kind with apanol to be unlikely. If all goes well, IZP is the next Amgen. If not - it's wallpaper.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News